Adaptive Biotechnologies CSO granted stock awards

Adaptive Biotechnologies Corp reported that Chief Scientific Officer Harlan S. Robins acquired shares of common stock through stock awards.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp reported that Chief Scientific Officer Harlan S. Robins acquired shares of common stock through stock awards. On March 6, 2026, he received 709,220 shares at a price of $0.00 per share, and on March 4, 2026, he received 127,813 shares at $0.00 per share.

These awards relate to performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026. The company certified achievement of the performance goals on March 6, 2026, and the performance share units vested on that date, resulting in common stock delivery.

Insider Trade Summary

Grant/Award: 837,033 shares

Grant/Award 2 txns

Insider ROBINS HARLAN S

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	709,220	$0.00	$0.00
Grant/Award	Common Stock	127,813	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,992,324 shares (Direct)

Footnotes (1)

1. F1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Adaptive Biotechnologies (ADPT) report for Harlan S. Robins?

Adaptive Biotechnologies reported that Chief Scientific Officer Harlan S. Robins acquired common stock through two stock awards. He received 709,220 shares on March 6, 2026, and 127,813 shares on March 4, 2026, both at a price of $0.00 per share as equity compensation.

How were the Adaptive Biotechnologies (ADPT) performance share units structured for Harlan S. Robins?

Each performance share unit represents a contingent right to receive one share of Adaptive Biotechnologies common stock. These units were granted on March 6, 2023, for a three-year performance period ending March 6, 2026, and would convert into common shares only if performance goals were achieved.

When did Adaptive Biotechnologies (ADPT) certify performance goals for Harlan S. Robins’ awards?

Adaptive Biotechnologies certified achievement of the performance goals on March 6, 2026. On that same date, the performance share units tied to the three-year period ending March 6, 2026 vested, triggering delivery of common stock to Chief Scientific Officer Harlan S. Robins as reported.

Did Harlan S. Robins pay cash for the Adaptive Biotechnologies (ADPT) shares he acquired?

No, Harlan S. Robins did not pay cash for these shares. Both reported acquisitions list a transaction price of $0.00 per share, indicating they were equity compensation awards delivered upon vesting of performance share units rather than open-market purchases.

How many Adaptive Biotechnologies (ADPT) shares did Harlan S. Robins hold after the reported transactions?

Following the March 6, 2026 stock award, Harlan S. Robins’ direct holdings were reported as 1,992,324 shares of Adaptive Biotechnologies common stock. After the March 4, 2026 award, his direct holdings were reported as 1,283,104 shares, reflecting the sequential impact of these equity grants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 07:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS HARLAN S

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		127,813	A	$0	1,283,104	D
Common Stock	03/06/2026		A(1)		709,220	A	$0	1,992,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 6, 2023, with respect to the three-year period ending on March 6, 2026. The issuer certified the achievement of the performance goals on March 6, 2026. The performance share units vested on March 6, 2026.

	/s/ Harlan S Robins by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.